Nation-state actors treat pharma like critical infrastructure targeting formulation data, synthesis routes, and clinical IP with patience and precision. Learn why standard pen testing misses this threat and what adversary simulation reveals instead.

Completing a pen test isn't enough for CMMC. Learn what C3PAO assessors actually look for in your evidence package and how to align your report, scope, POA&M, and remediation docs to specific practice statements.